JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties
- AnaptysBio price target raised to $52 from $36 at Guggenheim
- AnaptysBio: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Cautious Hold Rating on AnaptysBio Amid Uncertain Clinical Trial Outcomes and Strategic Decisions
- AnaptysBio Reports Strong Progress in Clinical Trials
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue